Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells

Stem Cells and Development

Volumn 18, Issue 4, 2009, Pages 573-581

  Di Bernardo, Giovanni ^a   Squillaro, Tiziana ^b   Dell'Aversana, Carmela ^a,c   Miceli, Marco ^c   Cipollaro, Marilena ^a   Cascino, Antonino ^a   Altucci, Lucia ^c   Galderisi, Umberto ^a,b,d  

^a Excellence Research Center for Cardiovascular Diseases   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; CASPASE 9; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROTEIN BAX; VORINOSTAT;

APOPTOSIS; ARTICLE; CELL AGING; CELL CYCLE ARREST; CELL FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SENESCENCE; TRANSACTIVATION;

APOPTOSIS; BENZAMIDES; CELL AGING; CELL CYCLE; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MESENCHYMAL STEM CELLS; NEOPLASMS; PYRIDINES;

EID: 67649271548     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2008.0172     Document Type: Article

References (46)

1. Spotswood HT and BM Turner. (2002). An increasingly complex code. J Clin Invest 110:577-582.
2. Rodriquez M, M Aquino, I Bruno, G De Martino, M Taddei and L Gomez-Paloma. (2006). Chemistry and biology of chroma-tin remodeling agents: state of art and future perspectives of HDAC inhibitors. Curr Med Chem 13:1119-1139.
3. Dokmanovic M and PA Marks. (2005). Prospects: histone deacetylase inhibitors. J Cell Biochem 96:293-304.
4. Heltweg B, F Dequiedt, BL Marshall, C Brauch, M Yoshida, N Nishino, E Verdin and M Jung. (2004). Subtype selective substrates for histone deacetylases. J Med Chem 47:5235-5243.
5. Duvic M, R Talpur, X Ni, C Zhang, P Hazarika, C Kelly, JH Chiao, JF Reilly, JL Ricker, VM Richon and SR Frankel. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39.
6. Duvic M and J Vu. (2007). Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16:1111-1120.
7. Ramalingam SS, RA Parise, RK Ramananthan, TF Lagattuta, LA Musguire, RG Stoller, DM Potter, AE Argiris, JA Zwiebel, MJ Egorin and CP Belani. (2007). Phase I and pharmacoki- netic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13:3605-3610.
8. Kummar S, M Gutierrez, ER Gardner, E Donovan, K Hwang, EJ Chung, MJ Lee, K Maynard, M Kalnitskiy, A Chen, G Melillo, QC Ryan, B Conley, WD Figg, JB Trepel, J Zwiebel, JH Doroshow and AJ Murgo. (2007). Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 13:5411-5417.
9. Ungerstedt JS, Y Sowa, WS Xu, Y Shao, M Dokmanovic, G Perez, L Ngo, A Holmgren, X Jiang and PA Marks. (2005). Role of thiore-doxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:673-678.
10. Muller-Sieburg CE and E Deryugina. (1995). The stromal cells' guide to the stem cell universe. Stem Cells 13:477-486.
11. Bianco P, M Riminucci, S Gronthos and P Gehron Robey. (2001). Bone marrow stromal stem cells: nature, biology and potential applications. Stem Cells 19:180-192.
12. Beyer Nardi N and L da Silva Meirelles. (2006). Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol:249-282.
13. Prockop DJ. (1997). Marrow stromal cells as stem cells for non- hematopoietic tissues. Science 276:71-74.
14. Sethe S, A Scutt and A Stolzing. (2006). Aging of mesenchymal stem cells. Ageing Res Rev 5:91-116.
15. Bianco P and P Gehron Robey. (2000). Marrow stromal stem cells. J Clin Invest 105:1663-1668.
16. Galderisi U, G Di Bernardo, M Cipollaro, G Peluso, A Cascino, R Cotrufo and MA Melone. (1999). Differentiation and apopto- sis of neuroblastoma cells: role of N-myc gene product. J Cell Biochem 73:97-105.
17. Minucci S and PG Pelicci. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51.
18. Kelly WK, OA O'Connor, LM Krug, JH Chiao, M Heaney, T Curley, B MacGregore-Cortelli, W Tong, JP Secrist, L Schwartz, S Richardson, E Chu, S Olgac, PA Marks, H Scher and VM Richon. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931.
19. Ryan QC, D Headlee, M Acharya, A Sparreboom, JB Trepel, J Ye, WD Figg, K Hwang, EJ Chung, A Murgo, G Melillo, Y Elsayed, M Monga, M Kalnitskiy, J Zwiebel and EA Sausville. (2005). Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23:3912-3922.
20. Campisi J and F d'Adda di Fagagna. (2007). Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8:729-740.
21. Cai J, ML Weiss and MS Rao. (2004). In search of "sternness". Exp Hematol 32:585-598.
22. Mikkers H and J Frisen. (2005). Deconstructing stemness. EMBO J 24:2715-2719.
23. Takahashi K and S Yamanaka. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676.
24. Gang EJ, SH Hong, JA Jeong, SH Hwang, SW Kim, IH Yang, C Ahn, H Han and H Kim. (2004). In vitro mesengenic potential of human umbilical cord blood-derived mesenchymal stem cells. Biochem Biophys Res Commun 321:102-108.
25. Gronthos S, AC Zannettino, SJ Hay, S Shi, SE Graves, A Kortesidis and PJ Simmons. (2003). Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 116:1827-1835.
26. Sodek J, B Ganss and MD McKee. (2000). Osteopontin. Crit Rev Oral Biol Med 11:279-303.
27. de Boer J, R Licht, M Bongers, T van der Klundert, R Arends and C van Blitterswijk. (2006). Inhibition of histone acetylation as a tool in bone tissue engineering. Tissue Eng 12:2927-2937.
28. Galderisi U, M Cipollaro and A Giordano. (2006). The retino- blastoma gene is involved in multiple aspects of stem cell biol-ogy. Oncogene 25:5250-5256.
29. Oberdoerffer P and DA Sinclair. (2007). The role of nuclear architecture in genomic instability and ageing. Nat Rev Mol Cell Biol 8:692-702.
30. Giacca A and M Kastan. (1998). The complexity of p53 modu-lation: emerging patterns from divergent signals. Genes Dev 12:2773-2783.
31. He L, X He, LP Lim, E de Stanchina, Z Xuan, Y Liang, W Xue, L Zender, J Magnus, D Ridzon, AL Jackson, PS Linsley, C Chen,
32. SW Lowe, MA Cleary and GJ Hannon. (2007). A microRNA component of the p53 tumour suppressor network. Nature 447:1130-1134.
33. Galderisi U, FP Jori and A Giordano. (2003). Cell cycle regulation and neural differentiation. Oncogene 22:5208-5219.
34. Baradari V, A Huether, M Hopfner, D Schuppan and H Scherubl. (2006). Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 13:1237-1250.
35. Sakajiri S, T Kumagai, N Kawamata, T Saitoh, JW Said and HP Koeffler. (2005). Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. ExpHematol 33:53-61.
36. Vrana JA, RH Decker, CR Johnson, Z Wang, WD Jarvis, VM Richon, M Ehinger, PB Fisher and S Grant. (1999). Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18:7016-7025.
37. Munro J, NI Barr, H Ireland, V Morrison and EK Parkinson. (2004). Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Exp Cell Res 295:525-538.
38. Xu WS, G Perez, L Ngo, CY Gui and PA Marks. (2005). Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 65:7832-7839.
39. Place RF, EJ Noonan and C Giardina. (2005). HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol 6:37.
40. Wagner M, G Brosch, W Zwerschke, E Seto, P Loidl and P Jansen-Durr. (2001). Histone deacetylases in replicative senes-cence: evidence for a senescence-specific form of HDAC-2. FEBS Lett 499:101-106.
41. Feinberg MW, AK Wara, Z Cao, MA Lebedeva, F Rosenbauer, H Iwasaki, H Hirai, JP Katz, RL Haspel, S Gray, K Akashi, J Segre, KH Kaestner, DG Tenen and MK Jain. (2007). The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation. EMBO J 26:4138-4148.
42. Qi H and D Pei. (2007). The magic of four: induction of pluripo- tent stem cells from somatic cells by Oct4, Sox2, Myc and Klf4. Cell Res 17:578-580.
43. Marks PA. (2004). The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 3:534-535.
44. Richon VM, TW Sandhoff, RA Rifkind and PA Marks. (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014-10019.
45. Muhlethaler-Mottet A, R Meier, M Flahaut, KB Bourloud, K Nardou, JM Joseph and N Gross. (2008). Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 7:55.
46. Yamasaki F, S Hama, H Yoshioka, Y Kajiwara, K Yahara, K Sugiyama, Y Heike, K Arita and K Kurisu. (2003). Staurosporine-induced apoptosis is independent of p16 and p21 and achieved via arrest at G2/M and at G1 in U251MG human glioma cell line. Cancer Chemother Pharmacol 51:271-283.